Comparative Pharmacology
Head-to-head clinical analysis: CALAN versus CARDIZEM LA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CALAN versus CARDIZEM LA.
CALAN vs CARDIZEM LA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Verapamil inhibits calcium ion influx through voltage-gated L-type calcium channels in cardiac and vascular smooth muscle, leading to decreased myocardial contractility, slowed AV conduction, and vasodilation.
Cardizem LA (diltiazem) is a calcium channel blocker that inhibits calcium ion influx across cardiac and smooth muscle cells during depolarization, leading to negative inotropic, chronotropic, and dromotropic effects. It dilates coronary and peripheral arteries, reducing systemic vascular resistance and myocardial oxygen demand.
Initial: 80-120 mg orally 3 times daily; maintenance: 240-480 mg/day in 3-4 divided doses. IV: 5-10 mg over 2 minutes, may repeat after 15-30 minutes.
Oral, 180-360 mg once daily; initiate at 180 mg once daily, titrate to 240 mg, then 300 mg, then 360 mg once daily as needed.
None Documented
None Documented
Terminal elimination half-life is 3-7 hours for immediate-release; can be prolonged to 12-16 hours with sustained-release due to slow absorption; increased in hepatic impairment.
Terminal elimination half-life: 5-8 hours after oral administration. For extended-release formulations, the half-life is similar but the prolonged absorption phase results in sustained plasma concentrations.
Approximately 70% renal (3-4% unchanged, remainder as metabolites) and 25% biliary/fecal.
Urine (2-4% unchanged, ~40% as metabolites); bile/feces (major route, ~60% as metabolites).
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker